Introduction {#s1}
============

Multiple myeloma (MM) is the second most common hematological malignancy, with an incidence ranging from 4 to 6 per 100,000/year in the United States ([@B12]). Malignant plasma cells display prominent genomic abnormalities arising during tumorigenesis and accumulating during disease progression. This series of complex molecular events involved in MM development includes chromosomal abnormalities, oncogene activation, and cellular communication signals dysregulation. MM treatment strategies have significantly evolved during the last decades with an expanding arsenal of anti-MM therapies. This was associated with a three-fold improvement in median survival. According to these significant advances, long-term side effects and harmful effects of treatment are an important issue with the development of drug-resistant subclones and formation of therapy-related cancers caused by lesions they create in normal cells. Thus, understanding the DNA damages induced by anti-MM therapies and DNA damage response is important to improve patient survival and reduce harmful effects related to treatment.

Genomic Instability in Multiple Myeloma {#s2}
=======================================

Genome integrity is constantly assailed by diverse arrays of insults. These include genotoxic agents of exogenous origin and endogenous sources of DNA damage, such as reactive oxygen species, collisions between DNA replication and transcription, and programmed genomic rearrangements ([@B1]). B cells are particularly challenged in this regard. During their maturation, B lymphocytes are subjected different to genetic alterations, including V, D and J immunoglobulin genes recombination, Ig class switch recombination (CSR), and somatic hypermutation (SHM). To prevent immune deficiency, autoimmunity, or cancer, these biological processes should be tightly regulated ([@B45]). MM cells are characterized by genomic instability, including chromosomal instability, mutations, and microsatellite instability. Recent genome sequencing studies of MM cells have uncovered the major genomic instability and molecular and subclonal heterogeneity of the disease ([@B74]; [@B126]).

DNA-Damaging Agents Used in Multiple Myeloma Treatment {#s3}
======================================================

Melphalan DNA-damaging agent was introduced for the treatment of MM in 1962. Several combinations have been developed to the improve outcome of patients, including other DNA-damaging agents ([**Table 1**](#T1){ref-type="table"}). The high-dose melphalan regimen combined with autologous hematopoietic stem cell transplant (ASCT) has long been considered frontline therapy for newly diagnosed patients. Melphalan is a nitrogen mustard known to induce mono-alkylation of adenine and guanine together with interstrand DNA crosslinks ([@B93]). Monoadducts represent 95% of the lesions, whereas 5% are interstrand DNA crosslinks (ICLs) ([@B83]). In MM cells, ICL number is correlated with the melphalan concentration used ([@B118]). ICLs are highly toxic for MM cells.

###### 

DNA-damaging chemotherapeutic drugs used in MM.

  Agents
  ----------------------------------------------------
  Melphalan (Alkeran^®^)
  Cyclophosphamide (Cytoxan^®^)
  Doxorubicin (Adriamycin^®^)
  Busulfan (Myleran^®^)
  Vincristine (Oncovin^®^)
  VP-16 (Etoposide^®^)
  Bendamustine (Treanda^®^)
  Pegylated liposomal doxorubicin (Doxil^®^)
  Melphalan flufenamide hydrochloride (Melflufen^®^)
  Cisplatin (Platinol^®^)

Results from studies with a long-term follow-up of patients treated with high-dose chemotherapy and ASCT demonstrated that 10%--15% of the patients remain alive after more than 10 years without relapse ([@B7]; [@B123]; [@B79]), demonstrating the efficacy of this strategy in MM ([@B124]). The novel drugs such as immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) used during induction, consolidation, and maintenance stages have significantly improved the outcome of the patients ([@B8]; [@B20]; [@B69]; [@B82]; [@B85]; [@B116]).

Other genotoxic drugs are used to treat patients with MM, including cyclophosphamide, doxorubicin, busulfan, vincristine, etoposide, cisplatin, bendamustine, lyposomal doxorubicin, and melphalan flufenamide hydrochloride. Use of chemotherapeutic agents without cross-resistance could enhance peripheral blood stem cell collection and improve patient outcome related to better antitumor efficacy before ASCT. Cyclophosphamide is an alkylating agent inducing ICLs. Doxorubicin induces DNA double-strand DNA breaks (DSBs) related to intercalation into DNA and inhibition of topoisomerase II (TopII). Doxorubicin can also induce DNA adducts, free radicals release, and formaldehyde-dependent ICL formation ([@B13]). Etoposide is a DNA-damaging agent that induces DNA damage and inhibits DNA replication by suppressing the relaxation activity of TopIIA topoisomerase ([@B36]). Busulfan is a bifunctional alkylating agent. Vincristine is a microtubule-targeting agent that was demonstrated to increase DNA damage induced by DNA-damaging agents ([@B101]). Cisplatin is a platinum compound that modifies DNA, leading to the formation of intrastrand or interstrand crosslinks between bases. Cisplatin is used in DCEP regimen in combination with dexamethasone, etoposide, and cyclophosphamide ([@B29]; [@B95]). Pegylated liposomal doxorubicin is a formulation of doxorubicin in liposomes with a prolonged circulation time ([@B129]). Bendamustine combines bifunctional alkylating nitrogen mustard group and a purine-like benzamidazol nucleus and was shown to overcome melphalan resistance in human myeloma cell lines ([@B24]). Melphalan flufenamide hydrochloride is a lipophilic alkylator characterized by intracellular hydrolysis after cellular uptake and release of active melphalan ([@B104]).

Drug Resistance Mechanisms to DNA-Damaging Agents {#s4}
=================================================

Drug Efflux, Cell Communication Signals, and Drug Metabolism {#s4_1}
------------------------------------------------------------

An important mechanism of multidrug resistance in cancer is the overexpression of ATP-binding cassette (ABC) transporters ([@B65]) ([**Figure 1**](#f1){ref-type="fig"}). This family of transmembrane proteins use the energy generated by ATP hydrolysis to efflux cytotoxic compounds. The most studied ABC is dependent efflux pump P-glycoprotein (P-gp) coded by the *MDR1/ABCB1* gene. In MM, no significant expression of P-gp was detected in newly diagnosed MM and in patients treated with melphalan ([@B49]). P-gp overexpression was demonstrated to be associated with resistance to glucocorticoid, etoposide, doxorubicin, and vincristine ([@B30]). VAD treatment (vincristine, doxorubicin, and dexamethasone) was associated with P-gp overexpression in MM patients ([@B115]; [@B136]). However, a clinical trial with ABCB1 inhibitor (Zosuquidar) did not show any benefit in progression-free or overall survival in refractory MM patients when combined with vincristine, doxorubicin, and dexamethasone ([@B42]).

![Mechanisms involved in DNA-damaging drug resistance in MM. Overview of mechanisms contributing to resistance to DNA-damaging agents in MM, including cellular extrusion of the drugs by ATP-dependent pumps, decreased drug influx, increased drug inactivation by metabolism, inactivation of apoptotic pathways, enhanced DNA repair, and altered cell cycle checkpoints and cell communication signals provided by the microenvironment.](fgene-10-00861-g001){#f1}

The behavior of MM cells is determined not only by their genetic or epigenetic background but also by their BM microenvironment. The majority of myeloma growth factors (MGFs) is secreted by the BM environment compared to autocrine MGFs ([@B76]). Several studies have provided a comprehensive overview of MGF expression in the different BM cell subpopulations of MM patients ([@B99]; [@B76]). Interactions between MM cells and bone marrow microenvironment could also play a role in DNA-damaging agents drug resistance ([**Figure 1**](#f1){ref-type="fig"}). We have documented the rise of large concentrations of IL-6 9 days after high-dose melphalan in patients ([@B25]). This large concentration of IL-6 will facilitate melphalan-resistant MMCs to survive within the BM. Patients treated with high-dose melphalan, stem cell transplantation, and anti-IL-6 antibody had a survival advantage when mixed with a large cohort of matched patients treated with melphalan and stem cell transplantation alone ([@B107]). Cell adhesion-mediated drug resistance to doxorubicin, vincristine, and melphalan was described using human myeloma cell lines and primary MM cells from patients ([@B31]; [@B89]; [@B86]; [@B34]). Bortezomib could overcome cell adhesion-mediated drug resistance through VLA-4 downregulation and inhibition of MM cell adhesion to stroma ([@B89]; [@B86]). Cell adhesion-mediated drug resistance could also protect MM cells from etoposide toxicity ([@B55]). Targeting cell-to-cell communication between MM cells and BM microenvironment could improve current therapeutic strategies using DNA-damaging agents.

*In vivo*, drugs could be metabolized ([**Figure 1**](#f1){ref-type="fig"}) through a number of reactions occurring through two distinct consecutive phases: phase I and phase II drug metabolism. Phase I drug metabolizing enzymes consist primarily of oxidases, reductases, and dehydrogenases, and phase II enzymes play an important role in biotransformation and inactivation of drugs. A study reported that MMCs of patients with a favorable outcome after treatment with high-dose therapy and ASCT are characterized by an overexpression of genes coding for xenobiotic receptors and their downstream targets, including phase I and phase II drug metabolism enzymes and transporters ([@B53]). At the opposite, high-risk patients were characterized by overexpression of genes involved in *Nrf2* and *ARNT* pathways ([@B53]). These data underline a role of drug metabolism in chemotherapy resistance in MM and suggest that inhibitors targeting these pathways could open new perspectives to alleviate or overcome drug resistance.

DNA-Damaging Agents and DNA Repair Pathways {#s4_2}
-------------------------------------------

The fact that DNA double-strand breaks are highly cytotoxic is exploited by DNA-damaging agents used in the treatment of MM. According to the type of DNA damage, specific DNA repair pathways will be used to cope with DNA insults. For nucleotide lesions occurring on single strands, base excision repair (BER), nucleotide excision repair (NER), and mismatch repair (MMR) will be involved. For DSBs, there are two major pathways, including nonhomologous end-joining (NHEJ) and homologous recombination (HR) DNA repair. The DNA damage response (DDR) sensor proteins will be involved in the detection of damaged DNA, leading to cellular response activation, including one or more DNA repair pathways. For DSBs, Ku proteins and MRN complex are the predominant sensors. Fanconi anemia proteins, Poly (ADP -ribose) polymerase (PARP), mismatch repair proteins (including MSH2, MSH3, MSH6, PMS2, and MLH1), and NER proteins (including XPC, CSA, and DDB2) are other DNA-damage sensors ([@B14]).

### Single-Strand Damage DNA Repair {#s4_2_1}

#### Nucleotide Excision Repair {#s4_2_1_1}

Nucleotide excision repair (NER) removes helix-distorting adducts on DNA that could be caused by UV or radiation and participates in the repair of ICLs44 ([**Figures 2**](#f2){ref-type="fig"} and [**3A**](#f3){ref-type="fig"}). NER can be coupled to transcription \[transcription-coupled nucleotide excision repair (TC-NER)\] opposed to global genome nucleotide excision repair (GG-NER) ([@B41]; [@B51]). In cancer cells exposed to genotoxic agents, NER plays a key role in removal and repair of the DNA damage ([@B66]). It has been demonstrated that NER is a major DNA repair mechanism that removes cisplatin-induced DNA damage. In solid tumors, high expression of ERCC1, involved in NER, is associated with resistance to platinum-based therapy. NER removes helix-distorting adducts participating in the ICL repair. ERCC1 and XP proteins play major roles in the repair of DNA adducts and ICLs ([**Figure 3A**](#f3){ref-type="fig"}). Furthermore, deficiency in NER was associated with higher sensitivity to platinum agents and a reduced capacity to repair ICLs ([@B66]).

![DNA single-strand damage repair. Base damages are repaired by base excision repair, bulky adducts by nucleotide excision repair, and base mismatch by mismatch repair pathway.](fgene-10-00861-g002){#f2}

![DNA interstrand crosslink repair. ICL repair can be initiated either at a stalled RNA polymerase **(A)** or at a replication fork **(B)**. **(A)** ICLs in DNA will stall RNA polymerase during transcription. The RNA polymerase will either backtrack or be degraded during subsequent repair involving translesion (TLS) polymerases and NER pathway. **(B)** The removal of ICL during S and G2 phases involves the Fanconi anemia pathway, with sensing of ICL by FANCM, and then recruitment of protein complex, resulting in ICL removal, creation of DSB, which is repaired by homologous recombination.](fgene-10-00861-g003){#f3}

#### Base Excision Repair {#s4_2_1_2}

The base excision repair (BER) pathway repairs DNA damaged bases ([@B73]) ([**Figure 2**](#f2){ref-type="fig"}). Conventional BER is initiated by specific DNA glycosylases that will hydrolyze N-glycosylic bond between the damaged base and the sugar phosphate backbone. This process is followed by end processing mechanism, repair synthesis, and ligation ([@B16]). However, different mechanisms could participate in BER pathways, depending on the physiological state of cancer cells and the type of DNA glycosylase involved ([@B16]).

#### Mismatch DNA Repair {#s4_2_1_3}

Mismatch DNA repair (MMR) is involved in the repair of replication errors associated with nucleotide deletion or insertion or causing incorporation of a wrong nucleotide ([**Figure 2**](#f2){ref-type="fig"}). MSH2-MSH6 defects in MMR are associated with drug resistance to temozolomide, nucleoside analogs, and platinum agents in solid cancers and Acute myeloid leukemia (AML) ([@B63]; [@B40]).

### DSBs DNA Repair {#s4_2_2}

DSBs can be generated during ICLs repair, by ROS, by DNA damaging used in MM treatment and during DNA replication when cells progress in S phase before completing single-strand DNA damage repair ([@B23]; [@B32]). Several partially independent sensors can detect DSBs, including Ku70/Ku80, PARP, MRN, and RPA. Homologous recombination operates in the S and G2 phases of the cell cycle. Homologous recombination pathway is conservative and requires a homologous DNA template ([**Figure 4**](#f4){ref-type="fig"}). At the opposite, NHEJ is nonconservative with direct ligation of DSB ends ([**Figure 4**](#f4){ref-type="fig"}).

![DNA double strand break repair. DSB are repaired by NHEJ or HRR pathways. NHEJ initiates with broken ends bound by Ku, which protects ends, leading to repair with partial resection and ligation of DNA ends. Alt-NHEJ is an alternative less accurate pathway. HRR is an accurate pathway. The DNA ends of the lesion are resected to allow invasion of the single strand into the sister chromatid used as a template for precise resynthesis of damaged DNA part. SSA is used only when two homologous regions flank the DSB site and is inaccurate.](fgene-10-00861-g004){#f4}

#### Homologous Recombination DNA Repair {#s4_2_2_1}

The homologous recombination DNA repair (HRR) pathway is complex and occurred during S and G2 phases of the cell cycle ([@B23]; [@B32]; [@B47]). The DNA ends of the lesion are resected to allow invasion of the single strand into the sister chromatid used as a template for precise resynthesis of damaged DNA part. HRR plays an important role in genomic stability ([@B27]; [@B28]). The MRN complex (MRE11-RAD50-NBS1) recognizes DSBs, and CtIP recruits RPA ([@B132]; [@B60]). BRCA1 interacts also with MRN and CtIP and promotes HRR and single-strand annealing (SSA). The resulting 3′ ssDNA tails are bound by RPA, which is replaced with Rad51. The reaction is mediated by Rad52, Rad55, and Rad57. The RAD51 nucleoprotein filament promotes homology search. This is followed by exchange strand between the intact sister chromatid and the broken duplex and strand extension by DNA polymerase ([**Figure 4**](#f4){ref-type="fig"}). HRR repairs DSBs, which occurs through exposure to topoisomerase inhibitors and DNA crosslinking agents used in MM treatment, including etoposide and doxorubicin. HRR plays a major role in stalled replication fork restart and ICL repair in association with the Fanconi anemia (FA) pathway ([**Figure 3B**](#f3){ref-type="fig"}). HRR is more active in MM cells compared to normal plasma cells ([@B113]; [@B106]). Higher expressions of RAD50 and RAD51 proteins involved in HRR have been reported in primary MM cells and MM cell lines compared to normal plasma cells in association with increased HRR activity ([@B113]; [@B106]). The proliferation assessment based on propidium iodide incorporation (plasma cell labeling index) ([@B110]) or the assessment of Ki-67-expressing cells of malignant plasma cells ([@B3]) has been shown to be a powerful and independent predictor of survival in MM. ([@B48]) The role of HRR in drug resistance of the small fraction of proliferating MM cells may be of particular importance in MM.

#### Single-Strand Annealing {#s4_2_2_2}

SSA is used only when two homologous regions flank the DSB site. In this context, the homologous regions are exposed, and after annealing and cleavage of the DNA overhang, ligation of the ends results in the deletion of the intervening region ([**Figure 4**](#f4){ref-type="fig"}). According to this process, SSA is inaccurate. Translocations induced by SSA have been reported when DSBs are located in repeats on different chromosomes ([@B52]; [@B23]).

#### NHEJ DNA Repair {#s4_2_2_3}

NHEJ does not use significant homology at the broken ends. DSBs are sensed by Ku70/Ku80 that bind and activate DNA-PKcs protein kinase, leading to the recruitment and activation of DNA end-processing enzymes, such as ARTEMIS, template-independent polymerases (polymerases λ and μ), and XLF-XRCC4-DNA ligase 4 complex ([**Figure 4**](#f4){ref-type="fig"}). More recently, several new accessory NHEJ factors, including PAXX/XLS and CYREN/MRI, have been described. These factors have been reported to be required for DNA ligation. PAXX/XLS is an accessory related to NHEJ pathway and presenting overlapping functions with XLF ([@B121]). CYREN is a cell cycle-dependent inhibitor of NHEJ pathway, promoting repair by HR pathway ([@B5]; [@B58]). A correlation between polymorphisms or aberrant expressions of *XRCC4, XRCC5* (encoding Ku80), *XRCC6* (encoding Ku70), *ARTEMIS*, and *LIG4* (encoding DNA ligase 4) genes and risk of MM development has been reported ([@B105]; [@B54]; [@B106]). Interestingly, high expression of *XRCC5* and *ARTEMIS* genes was associated with a poor prognosis in MM patients ([@B17]). A recent study investigated the functionality of DSB repair in MM cells and identified upregulation of ARTEMIS, DNA-PKcs, and XRCC4 proteins in MM cells ([@B56]). NHEJ activity was also significantly elevated in MM cells compared to a normal lymphoblastoid cell line ([@B56]). Furthermore, MMSET was recently identified to be involved in DNA damage response as a sensor ([@B50]). MMSET, like RIF1, is an ATM-dependent DDR factor. MMSET accumulates at DSBs, leading to recruitment of 53BP1. Recruitment of 53BP1 to DSBs is dependent on histone H4 methylation by MMSET ([@B96]). However, two other groups demonstrated that MMSET had no effect on 53BP1 foci formation and H4K20 methylation ([@B57]; [@B122]). During B-cell development, MMSET is also involved in class-switch recombination accumulating at immunoglobulin gene-switch regions with H3K36me2 and γH2AX. Furthermore, MMSET depletion led to defects in class-switch recombination ([@B97]). DSBs generated during CSR modifications of B-lymphocyte Ig genes are mainly repaired by NHEJ ([@B72]). H3K36 methylation, induced by MMSET and other histone methyltransferases, can also influence DNA repair pathway choice ([@B39]; [@B6]; [@B19]; [@B98]). More recently, it was shown that MMSET is necessary for efficient NHEJ and HRR ([@B111]). MMSET depletion resulted in decreased expression of DNA repair genes and significant reduction in the recruitment of DNA repair proteins at DNA damage sites. MMSET overexpression is associated with increased DNA repair efficiency. Loss of MMSET combined with melphalan treatment leads to decreased tumor mass and increased survival in mice ([@B111]). MMSET-overexpressing cells demonstrate increased γH2AX after treatment with DNA-damaging agents, suggesting a role in drug resistance through accelerated DNA repair ([@B111]). Given the association of t(4;14), involving MMSET, with poor outcome in MM, this potential perturbation of DNA repair may prove highly relevant to disease progression and drug resistance. More recently, [@B130] demonstrated that Dicer- and Drosha-dependent diRNAs play a role in guiding molecules to promote the recruitment of MMSET and other proteins to DSB sites. Several groups have demonstrated that H3K36 is the main target of MMSET without effect on H4K20 ([@B71]; [@B78]; [@B100]). Several studies reported that H3K36 mark favors NHEJ as DNA repair pathway choice ([@B39]; [@B6]; [@B19]; [@B94]; [@B98]). H3K36me2 increase and H3K27me3 decrease in MMSET-overexpressing cells are associated with a more open chromatin state ([@B78]; [@B100]). This chromatin state is associated with an increased DNA damage when cells are treated with a DNA-damaging agent ([@B111]). However, DNA repair proteins could access more easily to chromatin and facilitate efficient DNA repair ([@B103]; [@B117]), as observed in cells with high MMSET expressions ([@B111]).

#### Alternative NHEJ DNA Repair {#s4_2_2_4}

Alt-NHEJ is an alternative end-joining pathway that is detected when the classical NHEJ pathway is impaired ([@B90]; [@B81]) ([**Figure 4**](#f4){ref-type="fig"}). Alt-NHEJ is less accurate, requires more extensive end resection, and frequently uses microhomology. DNA ends are resected up to regions of microhomology, annealed, and ligated by XRCC1/ligases 1 and 3 ([@B23]; [@B112]; [@B114]; [@B10]). The 53BP1 protein protects DNA ends from nucleolytic degradation and thereby prevents microhomology mediated repair ([@B11]). Moreover, it has been implicated in the chromosomal translocation process involved in lymphoid tumorigenesis ([@B90]; [@B67]). Overexpression of proteins involved in alt-NHEJ, including DNA ligase 3, was also reported in MM cells ([@B56]). Activity of this highly mutagenic pathway was identified in MM cells through detection of largest deletions and higher sequence microhomology at DNA lesion sites and could be decreased by alt-NHEJ inhibition ([@B56]).

DNA Repair and Resistance to DNA-Damaging Agents in Multiple Myeloma {#s5}
====================================================================

Cyclophosphamide is a genotoxic agent inducing ICLs. Melphalan is also a nitrogen mustard that induces ICLs. The vast majority of the lesions induced by melphalan are monoadducts and 5% ICLs ([@B93]; [@B83]). The ICL number induced by melphalan in MM cells is correlated with the concentration used ([@B118]). Doxorubicin induces DNA adducts, DSB, free radicals release, and formaldehyde-dependent ICL formation. A study reported that MM cells from patients previously treated by melphalan are able to repair ICLs *in vitro*, whereas MM cells from untreated patients could not ([@B118]). Furthermore, melphalan-induced DNA damage, *in vitro*, in peripheral blood mononuclear cells is a predictor for clinical outcome in patients treated by high-dose melphalan and ASCT ([@B35]). A significant association between polymorphisms of genes involved in DNA repair and melphalan resistance was identified in MM ([@B37]). In a cohort of MM patients treated with high-dose melphalan and ASCT, polymorphisms of *PARP, RAD51, PCNA, OGG1, XPC, BRCA1, ERCC1, BARD1*, and *TP53BP1* are associated with the outcome and overall survival of patients ([@B37]). These genes are significantly enriched in genes involved in HRR and NER necessary for ICL repair. NER removes helix-distorting adducts on DNA and contributes to the repair of ICLs. Furthermore, reduced capacity to repair ICL has been associated with NER deficiency ([**Figure 3A**](#f3){ref-type="fig"}) together with higher sensitivity to platinum agents ([@B66]) ERCC2 and XRCC3 gene polymorphisms are associated with treatment outcome and drug resistance in patients treated with high-dose melphalan and ASCT ([@B125]). In MM cell lines resistant to melphalan, overexpression or *BRCA1*, *BRCA2*, *FANCA*, *FANCC*, *FANCF*, *FANCL*, and *RAD51C*; upregulation of HRR; and Fanconi pathways were identified. Depletion of FANCF could overcome melphalan resistance, and FANCF overexpression protects MM cells from melphalan toxicity ([@B22]). FA pathway appears as a key player in DNA-damaging agent resistance. NF-κB, constitutively activated in MM ([@B33]; [@B21]), was shown to transcriptionally regulate FA pathway genes ([@B137]). According to that, proteasome inhibitors affect DNA repair pathways in MM through several mechanisms. Proteasome inhibitors block NF-kB-mediated transcriptional activation of FA genes ([@B137]). PIs also inhibit the decrease in FANCD2 monoubiquitination and the expression of FANC proteins ([@B59]). PIs also target HRR by blocking NBS1, BRCA1, phospho-ATM, and Rad51 recruitment ([@B84]). PI treatment reduces the pool of available nuclear ubiquitin and impede FANCD2 and H2AX ubiquination ([@B87]). Bortezomib treatment may prevent DNA resection through inhibiting proteasomal degradation of proteins involved in chromatin relaxation ([@B59]; [@B84]). This mechanism impedes the recruitment of RPA onto ssDNA ([@B59]; [@B84]). This effect of PIs on DNA repair could explain the synergistic activity of PI treatment with high-dose melphalan before ASCT ([@B108]). MMSET was also involved in melphalan drug resistance through significant increases of DNA repair efficiency ([@B111]). Several studies demonstrated a role of BER in DNA-damaging agent resistance in MM. APE1 depletion was reported to sensitize MM cells to melphalan treatment ([@B80]). More recently, gene expression profile analyses revealed a prognostic value of genes involved in FA (*RMI1, FANCI*, and *FANCA*), NER (*PCNA, RPA3, LIG3, POLD3, ERCC4, POMD1, ERCC1*, and *ERCC5*), NHEJ \[*WHSC1* (MMSET), *RIF1, XRCC5* (Ku80), *PNKP*, and *POLL*\], MMR (*EXO1* and *MSH2*), and HRR (*EXO1, BLM, RPA3, RAD51, MRE11A*, and *ATM*) pathways in MM ([@B64]). Based on these prognostic genes, NHEJ, HRR, FA, and NER gene-based risk scores were created, allowing identification of high-risk MM patients in two independent cohorts of patients treated with high-dose melphalan and ASCT ([@B64]). Furthermore, a DNA repair risk score, incorporating all of the 22 DNA repair prognostic genes presented a strong prognostic value for both event-free survival and overall survival in two independent cohorts of MM patients. This gene-based DNA repair score remained an independent prognostic factor when tested together with known prognostic factors, including previously published [gene expression profiling (GEP)]{.ul}-based risk scores, t(4;14), del17p and with standard clinical prognostic factors, ISS, b2m, and albumin. These DNA repair scores represent powerful tools to develop synthetic lethality approaches and exploit the addiction of MM cells to a specific DNA repair pathway ([@B64]).

RECQ helicases playing a role in repair of damaged replication forks, DNA damage response, and homologous recombination are also involved in cancer cell drug resistance ([@B43]; [@B44]; [@B4]; [@B127]). In MM, high RECQ1 expression is associated with resistance to genotoxic agents and poor prognostic value in several independent cohorts of MM patients ([@B128]). MM cells overexpressing RECQ1 are able to repair DNA breaks induced by genotoxic agents more efficiently, conferring drug resistance ([@B128]). Interestingly, the abnormal overexpression of RECQ1 in MM is linked to aberrant methylation of miR-203. DNA methylation inhibitor treatment induces upregulation of miR-203 followed by RECQ1 downregulation and hypersensitivity to treatments ([@B128]).

In MM patients characterized by 1q21 amplification, high expression of ILF2 has also been reported to participate in resistance to genotoxic agents through regulation of DNA repair gene splicing transcription ([@B77]).

Mutagenic Effects of Chemotherapy in Multiple Myeloma {#s6}
=====================================================

Genotoxic agents can induce mutagenic effects. DNA alkylating agents and intercalating agents have been associated with mutations signatures ([@B120]). According to these effects, chemotherapy could cause harmful DNA damage associated with new driver genomic abnormalities, providing selective advantage, drug resistance, and higher relapse risk ([@B131]). Alkylating agents also modify the redox potential of cancer cells. This mechanism has been reported for melphalan and bendamustine that increase the level of reactive oxygen species (ROS), inhibit the activity of thioredoxin reductase, and activate p53 pathway ([@B133]; [@B119]). Interestingly, reduced glutathione (GSH) protects MM cells from melphalan-induced toxicity without affecting the ability of melphalan to induce DNA damage ([@B46]). Deregulation of genes involved in response to oxidative stress is associated with a poor outcome and Melphalan resistance in MM ([@B46]). The DNA damage accumulation resulting from survival advantage mediated by the redox system upregulation could participate in new genomic driver events and poor outcome in MM ([@B46]). In this context, the selective pressure of chemotherapy may result in new driver mutations associated with MM cell subclonal selection and drug resistance, as illustrated with double hit events involving tumor suppressor genes, including *TP53* and *FAM46C* in MM patients at relapse ([@B131]). Overexpression of DNA repair machinery could also result in new genomic events especially if nonaccurate pathways like alt-NHEJ are involved ([@B47]; [@B128]).

Synthetic Lethality Therapeutic Strategies to Overcome Drug Resistance {#s7}
======================================================================

DNA repair pathways and other pathways are deregulated in many MM patients to provide adaptive mechanisms and support drug resistance. Targeting DNA repair pathways may potentiate the efficacy of current drugs and overcome drug resistance and represents an opportunity to develop synthetic lethality approaches. Synthetic lethal strategies are currently developed in the context of the DNA damage response with the finding that PARP inhibitors are specifically toxic to HRR defective cancer cells ([@B15]; [@B38]). Because PI treatment was reported to induce BRCAness in MM cells, ([@B87]) this strategy was used for MM cells. Cotreatment of MMCs with bortezomib and PARP1 inhibitor resulted in DSB accumulation and MMC killing ([@B87]). Novel compounds targeting DNA repair pathways are being clinically evaluated in patients with cancer to induce synthetic lethality ([@B112]; [@B91]) ([**Table 2**](#T2){ref-type="table"}). These inhibitors targeting DNA repair pathways or cell cycle checkpoints (PARP1, DNA-PK, ATM, Ataxia telangiectasia and Rad3 related (ATR), MGMT, APE, CHK1, CHK2) could be useful to target MMCs in combination with DNA-damaging drugs and reverse drug resistance. The choice of which DNA repair inhibitor combine with the different DNA-damaging agents used in MM is related to align the DNA damage induced by the DNA-damaging agent with the DDR repair mechanism. PARP inhibitor was shown to reverse melphalan resistance in human myeloma cell lines, and combination with melphalan has synergistic association to FA and HRR pathways ([@B135]). ATR inhibitor also demonstrated significant anti-MM toxicity in the context of MYC-induced replicative stress ([@B26]). Interestingly, combination of ATR inhibitor with piperlongumine, a compound increasing ROS levels, exacerbates oncogene-induced DNA damage and shows a synergistic effect ([@B26]). CHK1/2 inhibitor AZD7762 was shown to potentiate the effects of melphalan, bendamustine, and doxorubicin in p53-deficient MM cell lines ([@B70]). Cyclin-dependent kinase (CDK) inhibitors have been identified to impair HRR and sensitize cancer cells to DNA-damaging agents ([@B62]; [@B102]). CDK1 and 2 phosphorylate BRCA1 with an important role in the formation of BRCA1 and RAD51 foci and HRR ([@B109]; [@B61]). CDK deregulation is a hallmark of MM, and CDK inhibitors are currently under clinical evaluation in MM ([@B9]; [@B68]; [@B88]). [@B2] demonstrated that dinaciclib, an inhibitor of CDK, impairs HRR in MM cells and sensitizes them to PARP inhibitor without toxicity to normal B cells. [@B75] reported DNA damage induction by DNA methyltransferase inhibitor decitabine in MM cells and stimulation of HRR and NHEJ pathways. Interestingly, combination with HDAC inhibitor or RAD51 inhibitor significantly enhances decitabine-mediated toxicity ([@B75]). These combinations could be of therapeutic interest in MM with conventional DNA-damaging agents. Several other epigenetic drugs have been shown to enhance the effect of DNA repair inhibitors in other cancers ([@B92]; [@B134]). Histone lysine methyltransferase inhibitors could prevent the BRCA1/BARD1 complex at DSBs ([@B134]).

###### 

DNA damage response inhibitors in clinical development.

  Target                      Compound
  --------------------------- --------------
  **BER**                     
  PARP                        Olaparib
                              Rucaparib
                              Niraparib
                              Talazoparib
                              Veliparib
  APE1                        Methoxyamine
  **HRR**                     
  ATR                         VX-970
                              AZD6738
  **NHEJ**                    
  DNA-PKcs                    MSC2490484A
                              CC-115
  **Checkpoint inhibitors**   
  CHK1                        GDC-0575
                              MK-8776
  CHK1 and CHK2               LY2606368
                              PF-00477736
  ATM                         AZD0156
  WEE1                        AZD11775

Achieving success in the clinic with targeted DNA repair inhibitors in combination with DNA-damaging agents will need identification of the MM cell-specific deregulation associated with susceptibility to a DNA repair inhibitor. The GEP-based DNA repair scores recently reported could be of interest in stratifying MM patients and target the addiction of malignant plasma cells to a specific DNA repair pathway. In addition, maximizing the therapeutic window by identifying the correct dose and schedule will be important. In this context, persistence of viable malignant MM cells, within bone marrow, 7 days after high-dose melphalan and ASCT has been reported in two thirds of the patients ([@B18]). This therapeutic window could be exploited for residual MM cell eradication before ASCT, taking advantage of new immune therapies presenting favorable toxicity profiles. Furthermore, modulating the redox system would be of therapeutic interest to optimize the use of genotoxic agents in MM ([@B46]).

Conclusion {#s8}
==========

Genotoxic agents cause DNA damage that can be recognized by DNA damage response pathways. The accumulation of unrepaired DNA lesions is associated with MM cell apoptosis. MM cells evading DNA damage-induced apoptosis may acquire new genomic alterations that could confer selective advantage and drug resistance. Several mechanisms associated with MMC resistance to genotoxic agents have been described, underlining the MM's endemic heterogeneous landscape. These findings provide several therapeutic strategies to overcome drug resistance and limit mutagenic effects of genotoxic agents in MM. According to this heterogeneity, adopting precision medicine into clinical practice has the potential to improve MM disease management and treatment. Furthermore, another limitation arises from adverse toxicity on normal cells and tissues, underlining the need to better understand the drug's mode of action to optimize between efficacy and harmful effects.
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